Literature DB >> 7539779

The effect of GM-CSF and G-CSF on human neutrophil function.

L A Bober1, M J Grace, C Pugliese-Sivo, A Rojas-Triana, T Waters, L M Sullivan, S K Narula.   

Abstract

A direct comparison of GM-CSF and G-CSF in a panel of in vitro neutrophil-function assays was performed to investigate any differences in activity profiles. In our modified chemotactic assay, GM-CSF rapidly increased the migratory capacity of polymorphonuclear cells (PMNs) to move toward fMLP and LTB4. In contrast, G-CSF only stimulated PMN migration towards fMLP. GM-CSF, but not G-CSF, increased PMN cytotoxic killing of C. albicans blastospores. The expression of PMN surface antigens associated with Fc- and complement-mediated cell-binding (Fc gamma R1, CR-1 and CR-3), and adhesion signalling (ICAM-1), was increased after the exposure of GM-CSF, but not to G-CSF. In contrast these CSFs demonstrated relative equipotency in their ability to induce PMN anti-bacterial phagocytosis, and to restore the Staphylococcus aureus killing capacity of dexamethasone-suppressed neutrophils. The phagocytic activity of PMNs for opsonized yeast, as well as hexose-monophosphate shunt activity, was equivalent following GM-CSF or G-CSF treatment. We discuss the significance of the difference in activity profiles in this article.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539779     DOI: 10.1016/0162-3109(94)00050-p

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  15 in total

1.  Evaluation of oral, subcutaneous, and nasal administration of Salmonella enteritidis-immune lymphokines on the potentiation of a protective heterophilic inflammatory response to Salmonella enteritidis in day-old chickens.

Authors:  M H Kogut; K Genovese; R B Moyes; L H Stanker
Journal:  Can J Vet Res       Date:  1998-01       Impact factor: 1.310

2.  A hampered chemoattractant-induced cytoskeletal rearrangement in granulocytes of patients with unexplained severe chronic and relapsing infections of the upper and lower airways. In vitro restoration by G-CSF exposure.

Authors:  P M J Kalkman; W J Fokkens; H J de Wit; J P van de Merwe; H Hooijkaas; J M W van Haarst; H C Hoogsteden; H A Drexhage
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

3.  Pharmacological characterization of human S1P4 using a novel radioligand, [4,5-3H]-dihydrosphingosine-1-phosphate.

Authors:  James Fossetta; Gregory Deno; Waldemar Gonsiorek; Xuedong Fan; Brian Lavey; Pradip Das; Charles Lunn; Paul J Zavodny; Daniel Lundell; R William Hipkin
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

Review 4.  Cancer therapeutic antibodies come of age: targeting minimal residual disease.

Authors:  Tsipi Ben-Kasus; Bilha Schechter; Michael Sela; Yosef Yarden
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

5.  Signaling mechanisms of enhanced neutrophil phagocytosis and chemotaxis by the polysaccharide purified from Ganoderma lucidum.

Authors:  Ming-Jen Hsu; Shiuh-Sheng Lee; Sho Tone Lee; Wan-Wan Lin
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

6.  Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice.

Authors:  L E Bermudez; M Petrofsky; P Stevens
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

7.  Successful Treatment of Invasive Conidiobolus Infection During Therapy for Acute Lymphoblastic Leukemia.

Authors:  Craig Erker; Anna R Huppler; Thomas J Walsh; Michael E McCormick; Mariko Suchi; Neel S Bhatt; Susan C Kehl; Jessica Southwood; Paul Harker-Murray
Journal:  J Pediatr Hematol Oncol       Date:  2018-10       Impact factor: 1.289

8.  Effect of a structurally modified human granulocyte colony stimulating factor, G-CSFa, on leukopenia in mice and monkeys.

Authors:  Yongping Jiang; Wenhong Jiang; Yuchang Qiu; Wei Dai
Journal:  J Hematol Oncol       Date:  2011-06-13       Impact factor: 17.388

9.  A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis.

Authors:  Yong Chen; Fang-Yuan Gong; Zhen-Jun Li; Zheng Gong; Zhe Zhou; Shu-Yan Ma; Xiao-Ming Gao
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

10.  Preferential production of G-CSF by a protein-like Lactobacillus rhamnosus GR-1 secretory factor through activating TLR2-dependent signaling events without activation of JNKs.

Authors:  Shahab Meshkibaf; Jӧrg Fritz; Marcelo Gottschalk; Sung Ouk Kim
Journal:  BMC Microbiol       Date:  2015-10-26       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.